Cargando…

The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes

In this paper, we assess the cost-effectiveness of 1 g daily of carnosine (an over the counter supplement) in addition to standard care for the management of type 2 diabetes and compare it to standard care alone. Dynamic multistate life table models were constructed in order to estimate both clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Kirthi, de Courten, Barbora, Magliano, Dianna J., Ademi, Zanfina, Liew, Danny, Zomer, Ella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747040/
https://www.ncbi.nlm.nih.gov/pubmed/35011089
http://dx.doi.org/10.3390/nu14010215
_version_ 1784630734350188544
author Menon, Kirthi
de Courten, Barbora
Magliano, Dianna J.
Ademi, Zanfina
Liew, Danny
Zomer, Ella
author_facet Menon, Kirthi
de Courten, Barbora
Magliano, Dianna J.
Ademi, Zanfina
Liew, Danny
Zomer, Ella
author_sort Menon, Kirthi
collection PubMed
description In this paper, we assess the cost-effectiveness of 1 g daily of carnosine (an over the counter supplement) in addition to standard care for the management of type 2 diabetes and compare it to standard care alone. Dynamic multistate life table models were constructed in order to estimate both clinical outcomes and costs of Australians aged 18 years and above with and without type 2 diabetes over a ten-year period, 2020 to 2029. The dynamic nature of the model allowed for population change over time (migration and deaths) and accounted for the development of new cases of diabetes. The three health states were ‘Alive without type 2 diabetes’, ‘Alive with type 2 diabetes’ and ‘Dead’. Transition probabilities, costs, and utilities were obtained from published sources. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per year of life saved (YoLS) and cost per quality-adjusted life year (QALY) gained. Over the ten-year period, the addition of carnosine to standard care treatment resulted in ICERs (discounted) of AUD 34,836 per YoLS and AUD 43,270 per QALY gained. Assuming the commonly accepted willingness to pay threshold of AUD 50,000 per QALY gained, supplemental dietary carnosine may be a cost-effective treatment option for people with type 2 diabetes in Australia.
format Online
Article
Text
id pubmed-8747040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87470402022-01-11 The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes Menon, Kirthi de Courten, Barbora Magliano, Dianna J. Ademi, Zanfina Liew, Danny Zomer, Ella Nutrients Article In this paper, we assess the cost-effectiveness of 1 g daily of carnosine (an over the counter supplement) in addition to standard care for the management of type 2 diabetes and compare it to standard care alone. Dynamic multistate life table models were constructed in order to estimate both clinical outcomes and costs of Australians aged 18 years and above with and without type 2 diabetes over a ten-year period, 2020 to 2029. The dynamic nature of the model allowed for population change over time (migration and deaths) and accounted for the development of new cases of diabetes. The three health states were ‘Alive without type 2 diabetes’, ‘Alive with type 2 diabetes’ and ‘Dead’. Transition probabilities, costs, and utilities were obtained from published sources. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per year of life saved (YoLS) and cost per quality-adjusted life year (QALY) gained. Over the ten-year period, the addition of carnosine to standard care treatment resulted in ICERs (discounted) of AUD 34,836 per YoLS and AUD 43,270 per QALY gained. Assuming the commonly accepted willingness to pay threshold of AUD 50,000 per QALY gained, supplemental dietary carnosine may be a cost-effective treatment option for people with type 2 diabetes in Australia. MDPI 2022-01-04 /pmc/articles/PMC8747040/ /pubmed/35011089 http://dx.doi.org/10.3390/nu14010215 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Menon, Kirthi
de Courten, Barbora
Magliano, Dianna J.
Ademi, Zanfina
Liew, Danny
Zomer, Ella
The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
title The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
title_full The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
title_fullStr The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
title_full_unstemmed The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
title_short The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
title_sort cost-effectiveness of supplemental carnosine in type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747040/
https://www.ncbi.nlm.nih.gov/pubmed/35011089
http://dx.doi.org/10.3390/nu14010215
work_keys_str_mv AT menonkirthi thecosteffectivenessofsupplementalcarnosineintype2diabetes
AT decourtenbarbora thecosteffectivenessofsupplementalcarnosineintype2diabetes
AT maglianodiannaj thecosteffectivenessofsupplementalcarnosineintype2diabetes
AT ademizanfina thecosteffectivenessofsupplementalcarnosineintype2diabetes
AT liewdanny thecosteffectivenessofsupplementalcarnosineintype2diabetes
AT zomerella thecosteffectivenessofsupplementalcarnosineintype2diabetes
AT menonkirthi costeffectivenessofsupplementalcarnosineintype2diabetes
AT decourtenbarbora costeffectivenessofsupplementalcarnosineintype2diabetes
AT maglianodiannaj costeffectivenessofsupplementalcarnosineintype2diabetes
AT ademizanfina costeffectivenessofsupplementalcarnosineintype2diabetes
AT liewdanny costeffectivenessofsupplementalcarnosineintype2diabetes
AT zomerella costeffectivenessofsupplementalcarnosineintype2diabetes